Post-earnings recap
Reported
Thu, Jul 29, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Edwards Lifesciences reported a strong EPS performance, exceeding expectations, which contributed to a 1.42% increase in stock price. The company did not provide revenue figures or future guidance, leaving some uncertainty for investors. Overall, the positive EPS surprise reflects the company's ongoing efforts in innovation and patient care.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.64 | N/A | +16.15% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on innovation and meeting patient needs.